Recent preclinical and early clinical data demonstrate that CAR-NK cells targeting antigens such as BCMA, SLAMF7, CD38, and GPRC5D effectively eliminate MM cells while maintaining a favorable safety profile. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.